Skip to main content

Table 4 Improvement in CNS-related symptoms

From: Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

 

Cohort 1, n = 20

Cohort 2, n = 32

Cohort 3, n = 13

Significant improvement in CNS-related symptoms (%)

75% (6/8)

78.6% (11/14)

83.3% (5/6)

Moderate improvement in CNS-related symptoms

25% (2/8)

7.1% (1/14)

16.7% (1/6)

No improvement in CNS-related symptoms

0

14.3% (2/14)

0

Deterioration in CNS-related symptoms

0

0

0